Low Total Lymphocyte Count Is Associated with Poor Survival in Patients with Resected Pancreatic Adenocarcinoma Receiving a GM-CSF Secreting Pancreatic Tumor Vaccine

被引：0
|
作者：
Aaron J. Schueneman
Elizabeth A. Sugar
Jennifer Uram
Elaine Bigelow
Joseph M. Herman
Barish H. Edil
Elizabeth M. Jaffee
Lei Zheng
Daniel A. Laheru
机构：
[1] Johns Hopkins University School of Medicine,Department of Oncology
[2] Johns Hopkins University School of Medicine,Department of Medicine
[3] Johns Hopkins University School of Medicine,Department of Surgery
[4] Johns Hopkins University School of Medicine,Department of Radiation Oncology
[5] Johns Hopkins University School of Medicine,The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care
[6] Johns Hopkins University School of Medicine,The Sol Goldman Pancreatic Cancer Center
[7] Johns Hopkins University,Departments of Biostatistics and Epidemiology, Bloomberg School of Public Health
[8] University of Colorado,Pancreas and Biliary Surgery Program, Department of Surgery
来源：
Annals of Surgical Oncology | 2013年 / 20卷
关键词：
Overall Survival; Pancreatic Cancer; Complete Blood Count; Lymphocyte Count; Ipilimumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：725 / 730
页数：5
相关论文
共 50 条
  • [41] The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone
    Shintakuya, Ryuta
    Kondo, Naru
    Murakami, Yoshiaki
    Uemura, Kenichiro
    Nakagawa, Naoya
    Okano, Keisuke
    Takahashi, Shinya
    Sueda, Taijiro
    PANCREATOLOGY, 2018, 18 (02) : 191 - 197
  • [42] Adverse Tumor Biology Associated with Mesenterico-Portal Vein Resection Influences Survival in Patients with Pancreatic Ductal Adenocarcinoma
    F. Wang
    A. J. Gill
    M. Neale
    V. Puttaswamy
    S. Gananadha
    N. Pavlakis
    S. Clarke
    T. J. Hugh
    J. S. Samra
    Annals of Surgical Oncology, 2014, 21 : 1937 - 1947
  • [43] Adverse Tumor Biology Associated with Mesenterico-Portal Vein Resection Influences Survival in Patients with Pancreatic Ductal Adenocarcinoma
    Wang, F.
    Gill, A. J.
    Neale, M.
    Puttaswamy, V.
    Gananadha, S.
    Pavlakis, N.
    Clarke, S.
    Hugh, T. J.
    Samra, J. S.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (06) : 1937 - 1947
  • [44] Baseline Metabolic Tumor Volume and Total Lesion Glycolysis Are Associated With Survival Outcomes in Patients With Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy
    Dholakia, Avani S.
    Chaudhry, Muhammad
    Leal, Jeffrey P.
    Chang, Daniel T.
    Raman, Siva P.
    Hacker-Prietz, Amy
    Su, Zheng
    Pai, Jonathan
    Oteiza, Katharine E.
    Griffith, Mary E.
    Wahl, Richard L.
    Tryggestad, Erik
    Pawlik, Timothy
    Laheru, Daniel A.
    Wolfgang, Christopher L.
    Koong, Albert C.
    Herman, Joseph M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 89 (03): : 539 - 546
  • [45] Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine
    Urey, Carlos
    Andersson, Bodil
    Ansari, Daniel
    Sasor, Agata
    Said-Hilmersson, Katarzyna
    Nilsson, Johan
    Andersson, Roland
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2017, 52 (05) : 595 - 600
  • [46] Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer
    Kawai, Manabu
    Hirono, Seiko
    Okada, Ken-ichi
    Miyazawa, Motoki
    Shimizu, Atsushi
    Kitahata, Yuji
    Kobayashi, Ryohei
    Ueno, Masaki
    Hayami, Shinya
    Tanioka, Kensuke
    Yamaue, Hiroki
    SURGERY, 2019, 165 (06) : 1151 - 1160
  • [47] Phase II study of GM-CSF secreting allogeneic pancreatic cancer vaccine (GVAX) with PD-1 blockade antibody and stereotactic body radiation therapy (SBRT) for locally advanced pancreas cancer (LAPC).
    Lee, Valerie
    Rodriguez, Christina
    Shupe, Ella-Mae
    Chen, Linda
    Parkinson, Rose
    Durham, Jennifer N.
    Sugar, Elizabeth
    Wilt, Cara
    McIntyre, Keith R.
    Hacker-Prietz, Amy
    Weiss, Matthew J.
    He, Jin
    Wolfgang, Christopher Lee
    De Jesus-Acosta, Ana
    Le, Dung T.
    Herman, Joseph M.
    Laheru, Daniel A.
    Narang, Amol
    Jaffee, Elizabeth M.
    Zheng, Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine
    J Nemunaitis
    N Senzer
    J Olivares
    P Kumar
    M Barve
    J Kuhn
    T Nemunaitis
    M Magee
    Y Yu
    G Wallraven
    B O Pappen
    P B Maples
    Gene Therapy, 2013, 20 : 875 - 879
  • [49] Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine
    Nemunaitis, J.
    Senzer, N.
    Olivares, J.
    Kumar, P.
    Barve, M.
    Kuhn, J.
    Nemunaitis, T.
    Magee, M.
    Yu, Y.
    Wallraven, G.
    Pappen, B. O.
    Maples, P. B.
    GENE THERAPY, 2013, 20 (09) : 875 - 879
  • [50] Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX
    van der Sijde, Fleur
    Azmani, Zakia
    Besselink, Marc G.
    Bonsing, Bert A.
    de Groot, Jan Willem B.
    Groot Koerkamp, Bas
    Haberkorn, Brigitte C. M.
    Homs, Marjolein Y. V.
    van IJcken, Wilfred F. J.
    Janssen, Quisette P.
    Lolkema, Martijn P.
    Luelmo, Saskia A. C.
    Mekenkamp, Leonie J. M.
    Mustafa, Dana A. M.
    van Schaik, Ron H. N.
    Wilmink, Johanna W.
    Vietsch, Eveline E.
    van Eijck, Casper H. J.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
12345